Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results.

ABSTRACT:

Background

The STAR-TReC trial is an international multi-center, randomized, phase II study assessing the feasibility of short-course radiotherapy or long-course chemoradiotherapy as an alternative to total mesorectal excision surgery. A new target volume is used for both (chemo)radiotherapy arms which includes only the mesorectum. The treatment planning QA revealed substantial variation in dose to organs at risk (OAR) between centers. Therefore, the aim of this study was to determine the treatment plan variability in terms of dose to OAR and assess the effect of a national study group meeting on the quality and variability of treatment plans for mesorectum-only planning for rectal cancer.

Methods

Eight centers produced 25 × 2 Gy treatment plans for five cases. The OAR were

SUBMITTER: van den Ende RPJ 

PROVIDER: S-EPMC7027245 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature